Elalfy, M. Et Al. 2014. Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis. PEDIATRIC BLOOD & CANCER , vol.61, no.5 , 879-884.

Elalfy, M., Wali, Y. A., Qari, M., Al Damanhouri, G., Al-Tonbary, Y., Yazman, D., ... Al Hawsawi, Z.(2014). Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis. PEDIATRIC BLOOD & CANCER , vol.61, no.5, 879-884.

Elalfy, Mohssen Et Al. "Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis," PEDIATRIC BLOOD & CANCER , vol.61, no.5, 879-884, 2014

Elalfy, Mohssen Et Al. "Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis." PEDIATRIC BLOOD & CANCER , vol.61, no.5, pp.879-884, 2014

Elalfy, M. Et Al. (2014) . "Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis." PEDIATRIC BLOOD & CANCER , vol.61, no.5, pp.879-884.

@article{article, author={Mohssen Elalfy Et Al. }, title={Deviating From Safety Guidelines During Deferiprone Therapy in Clinical Practice May Not be Associated With Higher Risk of Agranulocytosis}, journal={PEDIATRIC BLOOD & CANCER}, year=2014, pages={879-884} }